Patient Information Leaflet
Veriscal D1.500 mg/400 IU chewable tablets
(calcium carbonate/vitamin D3)
Read this leaflet carefully before you start taking this medicine, as it contains important information for you.
This medication is an association of calcium and vitamin D.
Veriscal D is indicated for the treatment of vitamin D deficiency states in patients who require calcium supplementation, as well as a vitamin D and calcium supplement associated with certain osteoporosis treatments.
Do not take Veriscal D
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take Veriscal D
Other medications and Veriscal D
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Certain medications may interact with this medication; in these cases, it may be necessary to change the dose, discontinue one of them, or wait at least a few hours between administration of both.
It is essential to inform your doctor if you are taking or have taken recently any of the following medications:
Veriscal D with food, drinks, and alcohol
If you take this medication with foods and drinks containing oxalic acid (present in spinach and rhubarb) or phytic acid (present in whole wheat bread and whole grain cereals), interactions may occur, so it is recommended not to take this medication during the two hours following the consumption of foods with high oxalic acid and phytic acid content.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
The consumption of medications during pregnancy can be hazardous to the embryo and fetus.
During pregnancy and breastfeeding, the daily intake should not exceed 1,500 mg of calcium and 600 IU of vitamin D3.
In pregnant women, excessive doses of vitamin D should be avoided, as prolonged maintenance of high calcium levels in the blood could cause alterations in the fetus.
Driving and operating machinery
No effects have been observed on the ability to drive and operate machinery.
Veriscal D contains sorbitol, aspartame, lactose, sucrose, and sodium
This medication contains 565.25 mg of sorbitol in each 232.04 mg/g equivalent tablet.
Sorbitol is a source of fructose. If your doctor has indicated that you (or your child) suffer from intolerance to certain sugars, or have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disease in which the patient cannot break down fructose, consult your doctor (or your child) before taking this medication.
This medication contains 5.00 mg of aspartame in each 2.05 mg/g equivalent tablet.
Aspartame contains a source of phenylalanine, which may be harmful in cases of phenylketonuria (PKU), a rare genetic disease in which phenylalanine accumulates due to the body's inability to eliminate it correctly.
This medication contains lactose. If your doctor has indicated that you suffer from intolerance to certain sugars, consult with them before taking this medication.
This medication contains sucrose. If your doctor has indicated that you suffer from intolerance to certain sugars, consult with them before taking this medication. It may cause tooth decay.
This medication contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially "sodium-free."
Interactions with diagnostic tests
If you are to undergo any diagnostic test (blood, urine...), inform your doctor that you are being treated with Veriscal D, as it may alter the results.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Remember to take your medication. The recommended dose is:
Adults : 1-2 chewable tablets per day, preferably after meals.
Use in children and adolescents
Consult your doctor to individualize the dose.
To carry out proper administration of the medication, chew the tablets well before swallowing, followed by a glass of water.
If you estimate that the action of this medication is too strong or too weak, inform your doctor or pharmacist.
If you take more Veriscal D than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562.04.20, indicating the medication and the amount ingested.
If you have taken more Veriscal D than you should, consult your doctor or pharmacist immediately.
Intentional or accidental overdose with chewable preparations is unlikely.
In case of overdose, you may experience a sensation of thirst, increased levels of calcium in the blood, increased levels of calcium in urine, anorexia, nausea, vomiting, abnormal emission of large amounts of urine, and calcium deposits in soft tissues.
If you forgot to take Veriscal D
Do not take a double dose to compensate for the missed doses, simply take the missed dose when you remember and take the next doses with the indicated interval (12 – 24 hours).
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications,this medicationmay cause adverse effects, although not everyone will experience them.
The following adverse effects have been observed:
Rare(may affect up to 1 in 100 people): hypercalcemia (elevated blood calcium levels) and hypercalciuria (elevated calcium levels in urine).
Uncommon(may affect up to 1 in 1,000 people): constipation, gas, nausea, abdominal pain, and diarrhea.
Mild digestive changes may occasionally occur. Veriscal D may stimulate the formation of kidney stones in patients with altered renal function.
If you consider any of the adverse effects you are experiencing to be severe or if you notice any adverse effect not mentioned in this leaflet, inform your doctor or pharmacist.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keepthis medicationout of the sight and reach of children.
Store in the original packaging to protect it from moisture.
Do not use this medication after the expiration date that appears on the packagingafter “CAD”. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or trash. Dispose of the containers and medications you no longer need at the SIGRE collection pointof the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of Veriscal D
The active principles are calcium carbonate and colecalciferol (vitamin D3).
Each tablet contains 1,500 mg of calcium carbonate (equivalent to 600 mg of calcium) and 400 IU of colecalciferol (vitamin D3) (equivalent to 0.01 mg).
The other components (excipients) are: sorbitol (E420), maltodextrin, lactose monohydrate, magnesium stearate, sodium croscarmellose, anise essence, peppermint essence, molasses essence, aspartame (E951), sodium saccharin, sucrose, gelatin, cornstarch, partially hydrogenated soybean oil, all-rac-α-tocopherol, and silicon dioxide.
Appearance of the product and contents of the packaging
Veriscal Dis presented in the form of white or almost white chewable tablets, marked with a D on one of its faces.
Each package contains 60 chewable tablets.
Holder of the marketing authorization
Laboratorios Farmacéuticos VALOMED, S.A.
C/ San Rafael, 3
28108 Alcobendas, Madrid
Spain
Responsible for manufacturing
ITALFARMACO S.p.A.
Viale Fulvio Testi, 330
20126 Milan
Italy
You can request more information about this medication by contacting the local representative of the holder of the marketing authorization
Italfarmaco, S.A.
C/ San Rafael, 3
28108 Alcobendas, Madrid
Spain
Last review date of this leaflet:August 2024
The detailed and updated information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es).
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.